Chemotherapy News and Research

Latest Chemotherapy News and Research

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

Research shows promise for developing a method of clearly identifying cancerous tissue during surgery

Research shows promise for developing a method of clearly identifying cancerous tissue during surgery

Mammography beneficial for women in their 40s, find researchers

Mammography beneficial for women in their 40s, find researchers

UNC researchers develop new radiation-free ultrasound technique to detect, monitor cancer

UNC researchers develop new radiation-free ultrasound technique to detect, monitor cancer

QUT researchers get new insight into ovarian cancer

QUT researchers get new insight into ovarian cancer

Researchers develop classification system to determine prognosis for bladder cancer

Researchers develop classification system to determine prognosis for bladder cancer

Everolimus fails to boost advanced NSCLC response

Everolimus fails to boost advanced NSCLC response

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

Researchers find novel drug combination approach to speed fight against cancer

Researchers find novel drug combination approach to speed fight against cancer

Study demonstrates direct effects of fragmented sleep on tumor growth

Study demonstrates direct effects of fragmented sleep on tumor growth

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

New drugs for treatment of prostate cancer may not target root cause of the disease

New drugs for treatment of prostate cancer may not target root cause of the disease

Immunotherapy maintenance shows promise in NSCLC

Immunotherapy maintenance shows promise in NSCLC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.